Treatment of elderly patients with refractory/relapsed multiple myeloma: oral drugs adherence and the COVID-19 outbreak
Metrics: PDF 197 views | Full Text 543 views | ?
Flávia Dias Xavier1,2, Fernando Sergio Blumm Ferreira2 and Rodrigo Martins Abreu3
1 Department of Hematology, Hospital Universitario de Brasilia-UNB/Ebserh, Brasilia, DF, Brazil
2 Hospital Sirio Libanes, Centro de Oncologia, Unidade Brasilia, Brasilia, DF, Brazil
3 Medical Affairs, Takeda Distribuidora Ltda., São Paulo, SP, Brazil
|Flávia Dias Xavier,||email:||email@example.com|
Keywords: healthcare; multiple myeloma; adherence; elderly; refractory/relapsed
Received: June 03, 2020 Accepted: October 17, 2020 Published: November 24, 2020
Once the treatment of refractory/relapsed multiple myeloma in the elderly is greatly influenced by the adherence of patients and family members, clinicians should be aware of patients’ behavior and lifestyle, as it may influence the individual treatment plan for each patient. Furthermore, treatment with oral chemotherapy is of special value during the COVID-19 outbreak. Multidisciplinary healthcare involvement is crucial in the management of polypharmacy, adverse events and dose adjustment due to comorbidities and natural loss of renal function with age. Oral drugs simplify intake, reduce hospital visits, and improve autonomy and quality of life. However, although oral drugs have advantages, they also transfer control and responsibility from the healthcare professional to the patient, who must be able to understand and follow the directions given. Therefore, patient education and communication with healthcare professionals are critical for adherence.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.